On July 17, 2019, a district court judge ruled in favor of Finnegan client Bausch Health Companies, upholding its patent covering Relistor®, a drug used for opioid-induced constipation. The ruling also states that Actavis’ generic version of the drug infringes the patent. In December 2016, Bausch sued Actavis after Actavis sought regulatory approval for a generic version of Relistor®, despite the fact that the patent for Relistor® doesn’t expire until March 2031. Actavis argued that MTNX—one of the ingredients found in the patented formula—had poor permeability and adding SLS—another ingredient in the patented formula—is an obvious fix. However, the judge disagreed and wrote, “The prior art cited by Actavis disclosed a wide array of options for a [person of skill in the art] faced with the purported permeability problem, with no reason to pick out SLS, which appears to be just one whitecap in a sea of choices.”
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.